The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pain sensitivity and aromatase inhibitor (AI)-associated arthralgias (AIAA).
Norah Lynn Henry
Research Funding - AstraZeneca
Steven Harte
No relevant relationships to disclose
Anna S.C. Conlon
No relevant relationships to disclose
Kent A. Griffith
No relevant relationships to disclose
Gabriela Ramirez
No relevant relationships to disclose
Jill Hayden
No relevant relationships to disclose
Jeffrey B. Smerage
No relevant relationships to disclose
Anne F. Schott
No relevant relationships to disclose
Daniel F. Hayes
Consultant or Advisory Role - Biomarker Strategies ; Inbiomotion
Stock Ownership - Medivation; OncImmune
Research Funding - Janssen Oncology; Novartis; Pfizer; Veridex
Other Remuneration - Veridex (Intellectual Property Interests)
David A. Williams
No relevant relationships to disclose
Daniel A Clauw
No relevant relationships to disclose